Positron Emission Tomography/Computed Tomography in Melanoma

Bourgeois, Austin C.; Chang, Ted T.; Fish, Lindsay M.; Bradley, Yong C.

doi:10.1016/j.rcl.2013.06.004

Cited by 17 publications

(13 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Practically speaking, this makes difficult the detection of subcentimeter metastases and precludes the detection of micrometastasis [23,30,31]. 18 F-FDG PET/ CT is also limited when assessing organs with high glucose uptake, such as the brain and liver, leading to uncertainty in the detection of cerebral and hepatic metastases [24,28,31,32]. In addition, evaluation of the genitourinary tract is limited because of the excretion of the radiotracer into the ureters and bladder [32].…”

Section: Positron Emission Tomography-computed Tomographymentioning

confidence: 99%

“…18 F-FDG PET/ CT is also limited when assessing organs with high glucose uptake, such as the brain and liver, leading to uncertainty in the detection of cerebral and hepatic metastases [24,28,31,32]. In addition, evaluation of the genitourinary tract is limited because of the excretion of the radiotracer into the ureters and bladder [32]. Furthermore, intravenous contrast enhanced 18 F-FDG PET/CT scans limit the detection of LN metastases near contrast agent-absorbing organs, arteries, and inflammatory areas [28,30].…”

Section: Positron Emission Tomography-computed Tomographymentioning

confidence: 99%

“…It is important to note that because immunotherapies used in the treatment of CM result in inflammation, they can affect the diagnostic accuracy of 18 F-FDG PET/CT. Finally, elevated serum insulin and glucose levels can impair the accuracy of 18 F-FDG PET/CT by altering the biodistribution of the tracer [32]. These factors limit the relative tumour uptake of 18 F-FDG, thus reducing the sensitivity in the detection of small lesions [32].…”

Section: Positron Emission Tomography-computed Tomographymentioning

confidence: 99%

See 2 more Smart Citations

The Pathogenesis and Clinical Management of Cutaneous Melanoma: An Evidence-Based Review

Burns

George

Aucoin

et al. 2019

Journal of Medical Imaging and Radiation Sciences

View full text Add to dashboard Cite

Cutaneous malignant melanoma (CM) is the leading cause of skin cancer-related mortality and accounts for approximately 1,250 deaths in Canada each year. It is also one of few cancers continuing to display rates of increasing incidence throughout the world. The past decade has brought significant growth in our understanding of the pathogenesis and clinical management of CM. This evidencebased review synthesizes that knowledge, beginning with a review of the epidemiology and etiology of the disease followed by a broad review of the roles of diagnostic imaging in its management. Special attention is given to the role of 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography-computed tomography (PET/CT) in supporting assessment at primary presentation of disease, follow-up to surgical and nonsurgical treatment, and for the surveillance of high-risk asymptomatic patients. After a brief review of current treatment options, this article concludes with a demonstration of how and when uncertainty exists at the point of care systematic review processes may be used to resolve clinical questions. Learning Objectives:By the end of this Continuing Medical Education article, participants will be able to 1. Describe the epidemiology and etiology of cutaneous melanoma, 2. Describe broadly the role of diagnostic imaging in the clinical management of cutaneous melanoma, 3. Describe the specific roles and limitations of 18 F-FDG PET/CT in the clinical management of cutaneous melanoma, 4. Describe broadly the best practice in the treatment of cutaneous melanoma, 5. Define the value of systematic review for synthesizing knowledge pertaining to a specific clinical question, and 6. Discuss the utility of 18 F FDG PET/CT in the management of early-stage (AJCC 0-IIc) cutaneous melanoma.This is a CME article and provides the equivalent of 2 hours of continuing education that may be applied to your professional development credit system. A 12-question multiple choice quiz follows this reading. Please note that no formalized credit (Category A) is available from CAMRT.

show abstract

Section: Positron Emission Tomography-computed Tomographymentioning

confidence: 99%

Section: Positron Emission Tomography-computed Tomographymentioning

confidence: 99%

Section: Positron Emission Tomography-computed Tomographymentioning

confidence: 99%

See 1 more Smart Citation

The Pathogenesis and Clinical Management of Cutaneous Melanoma: An Evidence-Based Review

Burns

George

Aucoin

et al. 2019

Journal of Medical Imaging and Radiation Sciences

View full text Add to dashboard Cite

show abstract

“…A large number of other PET radiopharmaceuticals for molecular imaging and personalized cancer management have also been reported, details of which can be found in recent review articles. 199–223 We would apologize to those whose work could not be presented here, mainly due to the vastness of the field and availability of enormous literature which could not be summarized in a single review.…”

Section: Carriers For Pet Image-guided Drug Deliverymentioning

confidence: 99%

Positron Emission Tomography Image-Guided Drug Delivery: Current Status and Future Perspectives

2014

View full text Add to dashboard Cite

Positron emission tomography (PET) is an important modality in the field of molecular imaging, which is gradually impacting patient care by providing safe, fast, and reliable techniques that help to alter the course of patient care by revealing invasive, de facto procedures to be unnecessary or rendering them obsolete. Also, PET provides a key connection between the molecular mechanisms involved in the pathophysiology of disease and the according targeted therapies. Recently, PET imaging is also gaining ground in the field of drug delivery. Current drug delivery research is focused on developing novel drug delivery systems with emphasis on precise targeting, accurate dose delivery, and minimal toxicity in order to achieve maximum therapeutic efficacy. At the intersection between PET imaging and controlled drug delivery, interest has grown in combining both these paradigms into clinically effective formulations. PET image-guided drug delivery has great potential to revolutionize patient care by in vivo assessment of drug biodistribution and accumulation at the target site and real-time monitoring of the therapeutic outcome. The expected end point of this approach is to provide fundamental support for the optimization of innovative diagnostic and therapeutic strategies that could contribute to emerging concepts in the field of “personalized medicine”. This review focuses on the recent developments in PET image-guided drug delivery and discusses intriguing opportunities for future development. The preclinical data reported to date are quite promising, and it is evident that such strategies in cancer management hold promise for clinically translatable advances that can positively impact the overall diagnostic and therapeutic processes and result in enhanced quality of life for cancer patients.

show abstract

“…Ao longo dos anos, os radiofármacos tem sido muito utilizados para o desenvolvimento de novas abordagens terapêuticas e diagnósticas (TRAN et al, 2009;KLEYNHANS et al, 2018), sendo também utilizados para entender processos de tumorigênese in vitro e in vivo, principalmente em tumores com elevada resistência a quimioterápicos, como no caso do melanoma (BOURGEOIS et al, 2013). Além disso, foi visto ter ocorrido alta captação do radiofármaco rituximabe-Tc 99m nos implantes sub cutâneos de melanoma, de animais inoculados com a linhagem B16F10, que foi detectado pelo aparelho SPECT/CT (Anexo A, Figura 2).…”

Section: )unclassified

Análise da função vascular de tumores gerados com linhagem de melanoma humano BRAFV600E em camundongos expostos a atividade física voluntária

Mororó¹,

Chammas²,

Buchpiguel³

View full text Add to dashboard Cite

Positron Emission Tomography/Computed Tomography in Melanoma

Cited by 17 publications

References 62 publications

The Pathogenesis and Clinical Management of Cutaneous Melanoma: An Evidence-Based Review

The Pathogenesis and Clinical Management of Cutaneous Melanoma: An Evidence-Based Review

Positron Emission Tomography Image-Guided Drug Delivery: Current Status and Future Perspectives

Análise da função vascular de tumores gerados com linhagem de melanoma humano BRAFV600E em camundongos expostos a atividade física voluntária

Contact Info

Product

Resources

About